Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Infect Dis Obstet Gynecol. 2007;2007:35387. doi: 10.1155/2007/35387.

Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women.

Author information

  • 1Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA 98195, USA. czajac@njc.org

Abstract

OBJECTIVES:

We performed a phase I trial to assess the safety and tolerance of a Lactobacillus vaginal suppository for prevention of recurrent UTI.

METHODS:

Premenopausal women with a history of recurrent UTI were randomized to use L. crispatus CTV-05 or placebo vaginal suppositories daily for five days.

RESULTS:

30 women were randomized (15 to L. crispatus CTV-05). No severe adverse events occurred. Mild to moderate vaginal discharge and genital irritation were reported by women in both study arms. Seven women randomized to L. crispatus CTV-05 developed pyuria without associated symptoms. Most women had high concentrations of vaginal H202-producing lactobacilli before randomization. L. crispatus, L. jensenii, and L. gasseri were the most common Lactobacillus species identified, with stable prevalence over time.

CONCLUSIONS:

L. crispatus CTV-05 can be given as a vaginal suppository with minimal sideeffects to healthy women with a history of recurrent UTI. Mild inflammation of the urinary tract was noted in some women.

PMID:
18288237
[PubMed - indexed for MEDLINE]
PMCID:
PMC2216064
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk